Table of Content

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview
Genome Editing
CRISPR
Introduction
Components of CRISPR
Mechanism of Action
CRISPR Gene Editing Workflow
Advantages and Disadvantages of CRISPR Technology
Pricing Analysis
PESTLE Analysis
Porter’s Five Forces Analysis
Regulatory Landscape, by Type
Human
Gene Drives
Agriculture
Animals
Regulatory Landscape, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 3 Market Dynamics
Market Dynamics Snapshot
Market Drivers
Rising Incidence of Chronic Diseases
Prevalence of Genetic Disorders
Government and Private Funding
Market Restraints
Alternative Technologies
Market Opportunities
Increase in the Number of Applications
Market Challenges
Complex and Evolving Regulatory Landscape
High Cost of CRISPR-based Therapy

Chapter 4 Emerging Technologies and Developments
Emerging Technologies
In Vivo Delivery of CRISPR
Improved Cas Variants
Artificial Intelligence
Clinical Trials Analysis
Clinical Trials Analysis, by Type of Study
Clinical Trials Analysis, by Status
Clinical Trials Analysis, by Phase
Clinical Trials
Patent Analysis
Patents, by Year
Patents, by Top Applicant
Patents, by Top Owner
Patents, by Jurisdiction
Intellectual Property Disputes and Patent Issues

Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Market Breakdown, by Application
Drug Development
Agriculture
Diagnostics
Other Applications
Market Breakdown, by End User
Biotech and Pharmaceutical Companies
Academics and Government Research Institutes
Contract Research Organizations
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 Competitive Intelligence
Market Analysis
Strategic Analysis

Chapter 7 Sustainability in CRISPR Technology: An ESG Perspective
Introduction to ESG
Sustainability in CRISPR Technology: An ESG Perspective
Key ESG Issues
CRISPR Technology ESG Performance Analysis
Environmental Performance
Social Performance
Governance Performance

Chapter 8 Appendix
Methodology
References
Abbreviations
Company Profiles
AGILENT TECHNOLOGIES INC.
BEAM THERAPEUTICS
CARIBOU BIOSCIENCES INC.
CRISPR THERAPEUTICS
DANAHER CORP.
EDITAS MEDICINE
GENSCRIPT
INTELLIA THERAPEUTICS INC.
LONZA
MERCK KGAA
THERMO FISHER SCIENTIFIC INC.



List of Figures


Summary Figure : Global Market for CRISPR Technology, by Application, 2021-2029
Figure 1 : CRISPR: Mechanism of Action
Figure 2 : CRISPR Gene Editing: Workflow
Figure 3 : Advantages and Disadvantages of CRISPR Technology
Figure 4 : PESTLE Analysis – CRISPR Technology
Figure 5 : Market Dynamics of CRISPR Technology
Figure 6 : Estimated Numbers of All Cancer Cases, Both Sexes, 2022-2050
Figure 7 : Global Estimates: People with Diabetes (20 to 79), 2021-2045
Figure 8 : Emerging Trends/Technologies in the CRISPR Technology Market
Figure 9 : Patents Granted on CRISPR Technology, by Year, 2020-2022
Figure 10 : Global Market Shares for CRISPR Technology, by Application, 2023
Figure 11 : CRISPR Technology in Drug Development
Figure 12 : Uses of CRISPR in Agriculture
Figure 13 : Global Market Shares for CRISPR Technology, by End User, 2023
Figure 14 : Number of Scientific Publications on CRISPR, by Year, 2020-2023
Figure 15 : Global Market Shares for CRISPR Technology, by Region, 2023
Figure 16 : North American Market Shares of CRISPR Technology, by Country, 2023
Figure 17 : U.S. Market for CRISPR Technology, 2021-2029
Figure 18 : Canadian Market for CRISPR Technology, 2021-2029
Figure 19 : European Market Shares of CRISPR Technology, by Country, 2023
Figure 20 : German Market for CRISPR Technology, 2021-2029
Figure 21 : U.K. Market for CRISPR Technology, 2021-2029
Figure 22 : French Market for CRISPR Technology, 2021-2029
Figure 23 : Rest of the European Market for CRISPR Technology, 2021-2029
Figure 24 : Asia-Pacific Market Shares of CRISPR Technology, by Country, 2023
Figure 25 : Chinese Market for CRISPR Technology, 2021-2029
Figure 26 : Japanese Market for CRISPR Technology, 2021-2029
Figure 27 : Indian Market for CRISPR Technology, 2021-2029
Figure 28 : Rest of Asia-Pacific Market for CRISPR Technology, 2021-2029
Figure 29 : RoW Market for CRISPR Technology, 2021–2029
Figure 30 : Pillars of ESG
Figure 31 : Advantages of ESG for Companies
Figure 32 : Methodology Used in the CRISPR Technology Market
Figure 33 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2023
Figure 34 : Agilent Technologies Inc.: Revenue Share, by Region, FY 2023
Figure 35 : Caribou Biosciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 36 : Caribou Biosciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 37 : Danaher Corp.: Market Share, by Business Unit, FY 2023
Figure 38 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023
Figure 39 : GenScript: Revenue Share, by Business Unit, FY 2023
Figure 40 : GenScript: Revenue Share, by Country/Region, FY 2023
Figure 41 : Lonza: Revenue Share, by Business Unit, FY 2023
Figure 42 : Lonza: Revenue Share, by Country/Region, FY 2023
Figure 43 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 44 : Merck KGaA: Revenue Share, by Region, FY 2023
Figure 45 : Thermo Fisher Scientific Inc.: Market Share, by Business Unit, FY 2023
Figure 46 : Thermo Fisher Scientific Inc.: Revenue Share, by Region, FY 2023

List of Tables


Summary Table : Global Market for CRISPR Technology, by Application, Through 2029
Table 1 : Comparison of Genome Editing Techniques
Table 2 : Comparison of sgRNA Formats
Table 3 : Comparison of Cas Enzymes
Table 4 : Pricing Analysis of CRISPR Technology Products, by Company
Table 5 : Regulatory Rating: Human Gene Editing, by Country/Region
Table 6 : Regulatory Rating: Gene Drives, by Country/Region
Table 7 : Regulatory Rating: Crops/Food, by Country/Region
Table 8 : Regulatory Rating: Animals, by Country/Region
Table 9 : Regulatory Landscape in Asia-Pacific Countries
Table 10 : Regulatory Landscape in South American Countries
Table 11 : Chronic Diseases: Applications of CRISPR-based Therapy
Table 12 : Genetic Disease: CRISPR-based Therapy
Table 13 : CRISPR Technology: Venture Funding, 2021–2024
Table 14 : Clinical Trials in CRISPR Technology, by Type of Study, August 2024
Table 15 : Clinical Trials in CRISPR Technology, by Status, August 2024
Table 16 : Clinical Trials in CRISPR Technology, by Phase, August 2024
Table 17 : Select Clinical Trials, 2024
Table 18 : Patents Granted on CRISPR Technology, by Top Applicant, 2020-2023
Table 19 : Patents Granted on CRISPR Technology, by Top Owner, 2020–2023
Table 20 : Patents Granted on CRISPR Technology, by Jurisdiction, 2020-2023
Table 21 : Global Market for CRISPR Technology, by Application, Through 2029
Table 22 : CRISPR-Based Genetic Therapy: Pipeline, 2024
Table 23 : Global Market for Drug Development in CRISPR Technology, by Region, Through 2029
Table 24 : CRISPR-Edited Crops
Table 25 : Global Market for Agriculture in CRISPR Technology, by Region, Through 2029
Table 26 : CRISPR-based Diagnostics
Table 27 : Global Market for Diagnostics in CRISPR Technology, by Region, Through 2029
Table 28 : Global Market for Other Applications in CRISPR Technology, by Region, Through 2029
Table 29 : Global Market for CRISPR Technology, by End User, Through 2029
Table 30 : Biotech and Pharmaceutical Partners of CRISPR Technology Companies
Table 31 : Recent Collaborations Among Biotech, Pharma and CRISPR Technology Firms, 2023-2024
Table 32 : Global Market for Biotech and Pharma Companies for CRISPR Technology, by Region, Through 2029
Table 33 : Global Market for Academics and Government Research Institutes for CRISPR Technology, by Region, Through 2029
Table 34 : Global Market for CRO for CRISPR Technology, by Region, Through 2029
Table 35 : Global Market for CRISPR Technology, by Region, Through 2029
Table 36 : North American Market for CRISPR Technology, by Country, Through 2029
Table 37 : European Market for CRISPR Technology, by Country, Through 2029
Table 38 : Asia-Pacific Market for CRISPR Technology, by Country, Through 2029
Table 39 : Leading Companies in the CRISPR Technology Market
Table 40 : Small and Medium-Sized Companies in the CRISPR Technology Market
Table 41 : Recent Developments in the CRISPR Technology Market, 2022-2024
Table 42 : Bioethical Issues and Risks Associated with CRISPR Technology
Table 43 : ESG Rankings for CRISPR Technology Companies, 2024*
Table 44 : ESG: Environmental Overview
Table 45 : ESG: Social Overview
Table 46 : ESG: Governance Overview
Table 47 : Information Sources in this Report
Table 48 : Abbreviations Used in this Report
Table 49 : Agilent Technologies Inc.: Company Snapshot
Table 50 : Agilent Technologies Inc.: Financial Performance, FY 2022 and 2023
Table 51 : Agilent Technologies Inc.: Product Portfolio
Table 52 : Agilent Technologies Inc.: News/Key Developments, 2021
Table 53 : Beam Therapeutics: Company Snapshot
Table 54 : Beam Therapeutics: Financial Performance, FY 2022 and 2023
Table 55 : Beam Therapeutics: Product Portfolio
Table 56 : Beam Therapeutics: News/Key Developments, 2021-2023
Table 57 : Caribou Biosciences Inc.: Company Snapshot
Table 58 : Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
Table 59 : Caribou Biosciences Inc.: Product Portfolio
Table 60 : Caribou Biosciences Inc.: News/Key Developments, 2021-2023
Table 61 : CRISPR Therapeutics: Company Snapshot
Table 62 : CRISPR Therapeutics: Financial Performance, FY 2022 and 2023
Table 63 : CRISPR Therapeutics: Product Portfolio
Table 64 : CRISPR Therapeutics: News/Key Developments, 2022-2024
Table 65 : Danaher Corp.: Company Snapshot
Table 66 : Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 67 : Danaher Corp.: Product Portfolio
Table 68 : Danaher Corp.: News/Key Developments, 2021-2024
Table 69 : Editas Medicine: Company Snapshot
Table 70 : Editas Medicine: Financial Performance, FY 2022 and 2023
Table 71 : Editas Medicine: Product Portfolio
Table 72 : Editas Medicine: News/Key Developments, 2022 and 2023
Table 73 : GenScript: Company Snapshot
Table 74 : GenScript: Financial Performance, FY 2022 and 2023
Table 75 : GenScript: Product Portfolio
Table 76 : GenScript: News/Key Developments, 2021
Table 77 : Intellia Therapeutics Inc.: Company Snapshot
Table 78 : Intellia Therapeutics Inc.: Financial Performance, FY 2022 and 2023
Table 79 : Intellia Therapeutics Inc.: Product Portfolio
Table 80 : Intellia Therapeutics Inc.: News/Key Developments, 2021-2023
Table 81 : Lonza: Company Snapshot
Table 82 : Lonza Financial Performance, FY 2022 and 2023
Table 83 : Lonza: Product Portfolio
Table 84 : Lonza: News/Key Developments, 2022-2024
Table 85 : Merck KGaA: Company Snapshot
Table 86 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 87 : Merck KGaA: Product Portfolio
Table 88 : Merck KGaA: News/Key Developments, 2021
Table 89 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 90 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 91 : Thermo Fisher Scientific Inc: Product Portfolio
Table 92 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021 and 2022